The short answer
Do not add L-tryptophan supplements to desipramine without prescriber review. The drug label names tryptophan in its serotonin-syndrome warning, and small older studies do not establish routine combination safety.
What this answer covers
Concentrated L-tryptophan supplements; ordinary dietary protein is not the studied exposure. IV challenge studies are separate from oral supplementation.
- Supplement or preparation
- L-Tryptophan
- Medication ingredient
- desipramine
The exact label supports a precaution
Desipramine’s prescribing information names tryptophan among products that may increase serotonin-syndrome risk. It does not instruct patients to restrict ordinary protein foods.
An older combination study did not show faster recovery
Desipramine plus tryptophan was one regimen in an older depression study, but no treatment group showed accelerated recovery. The abstract does not provide enough safety detail to approve routine use.
A challenge test is not a supplement safety trial
IV tryptophan produced a larger prolactin response after desipramine treatment. That hormone finding does not quantify toxicity from an oral supplement or define a safe dose.
Recognize concerning symptoms
Seek urgent medical care for a combination of agitation or confusion, fever or heavy sweating, tremor, muscle rigidity or repeated twitching. These can be signs of serotonin syndrome; a single nonspecific symptom does not establish the diagnosis.
Evidence and practical considerations
Side effects & toxicity
Label-supported conditional serotonin precaution remains appropriate despite experimental co-use and physiological challenge research.
- Exact scope
- Concentrated L-tryptophan supplements; ordinary dietary protein is not the studied exposure. IV challenge studies are separate from oral supplementation. with Exact oral desipramine hydrochloride tablets. RxNorm IN 3247/PIN 203174 hydrochloride. Mainly norepinephrine reuptake activity does not erase the exact label’s serotonin warning. CYP2D6 inhibition can affect concentrations; not assumed identical to CYP3A substrates.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- Older treatment abstract gives limited dose, route and safety detail. IV prolactin response is a surrogate, not a toxicity event or an oral dose recommendation.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral desipramine.
Exact label warns about serotonin syndrome with tryptophan and St John’s wort, CYP2D6 inhibition, impaired alertness and cardiovascular/anticholinergic effects.
How this applies: RxNorm IN 3247/PIN 203174 hydrochloride. Mainly norepinephrine reuptake activity does not erase the exact label’s serotonin warning. CYP2D6 inhibition can affect concentrations; not assumed identical to CYP3A substrates.
No universal supplement interval, event rate or preparation equivalence established. Original label distinguishes warnings from measured pair-specific results.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Unipolar depressed patients in several treatment groups.
No group showed evidence of accelerated recovery.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
Older abstract does not supply adequate route, dose or safety detail; lack of accelerated recovery is not proof of combination safety.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Depressed patients, including seven receiving desipramine.
Prolactin response to tryptophan increased with desipramine.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
IV precursor and hormone surrogate, not oral-supplement toxicity or an estimate of serotonin syndrome risk.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. | |
| Research summary published |
Article revision: 1152e068e72f05a6
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.